MedPath

Remotely Monitored Exercise Program in Pregnant Women With Obesity

Not Applicable
Conditions
Pregnancy Related
Obesity, Maternal
Interventions
Behavioral: Remote Exercise
Registration Number
NCT05331586
Lead Sponsor
Universidade do Porto
Brief Summary

Pregnant women with obesity will be invited to participate in structured home-based exercise programme, remotely monitored

Detailed Description

Pregnant women with obesity will be invited to participate in structured home-based exercise programme, remotely monitored. The remote system use inertial motion trackers, digitizes pregnant women motion and provides real-time feedback on performance through a mobile app. It also includes a web-based platform that allows the clinical team to prescribe, monitor and adapt the exercise program remotely. This way, the system allows patients to perform independent exercise program at home without the need for constant therapist supervision, ensuring remote monitoring throughout the rehabilitation program. The exercise programme will be performed since the first gestational trimester until delivery.

Data of gestational weight gain, gestational diabetes mellitus, low back pain and quality of life will be colected.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Pregnant women with obesity (BMI ≥ 30 kg/m2) at first gestational trimester
Exclusion Criteria
  • pre-pregnancy BMI < 30 kg/m2;
  • previous bariatric surgery;
  • hemodynamically significant heart disease;
  • restrictive lung disease;
  • incompetent cervix or cerclage;
  • multiple gestation;
  • persistent second- or third-trimester bleeding;
  • placenta previa after 26 weeks of gestation;
  • premature labor during the current pregnancy;
  • ruptured membranes;
  • preeclampsia or pregnancy-induced hypertension;
  • severe anemia;
  • inability to read and understand Portuguese; ->15 weeks gestation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Exercise interventionRemote ExerciseThe exercise group intervention will perform home-based remotely monitored exercise
Primary Outcome Measures
NameTimeMethod
Excessive gestational weight gainAt delivery

The adequate gestational weight gain in pregnant women with obesity should not exceed 9kg in entire pregnancy, the values over these thresholds will be considered excessive gestational weight gain.

Gestational Weight GainAt delivery

Using portable digital scale (Tantita InnerScan BC-545). Gestational weight gain will be calculated as the difference between maternal weight at last appointment (36-39 gestational weeks) and pre-pregnancy weight.

Secondary Outcome Measures
NameTimeMethod
Quality of Life AssessmentAt first, second and third gestational trimester

COOP-Quality of life during Pregnancy Questionnaire

Subjective Physical Activity assessmentAt first, second and third gestational trimester

Pregnancy Physical Activity Questionnaire (PPAQ) is a self-reported questionnaire. The objective is measure the type and intensity of pregnant women physical activity.

Pelvic Floor and sexual disorders during pregnancyAt first, second and third gestational trimester

Assessment of Pelvic Floor Disorders and Their Risk Factors During Pregnancy and Postpartum Questionnaire

Low Back PainAt first, second and third gestational trimester

Oswestry Low Back Pain Disability Questionnaire (ODI v2.0)

Objective Physical Activity assessmentAt first, second and third gestational trimester

Accelerometry, is a device that monitors the acceleration of body segments, it is considered the gold standard with regard to objectivity and reliability (ICC:0.661-0.806)

Gestational Diabetes MellitusSecond gestational trimester

The presence of gestational diabetes mellitus will be assessed between 24-28 gestation weeks, through the Oral Glucose Tolerance Test. Blood sampling for fasting glucose concentrations will be taken after a 10 hour overnight fast, and glucose tolerance will measured by a 2 hours 75 mg per-oral glucose tolerance test. GDM will be diagnosed as fasting glucose ≥ 126 mg/dl or 2h concentration ≥ 200 mg/dl.

Trial Locations

Locations (1)

Diana Bernardo

🇵🇹

Porto, Portugal

© Copyright 2025. All Rights Reserved by MedPath